JNJ - Johnson & Johnson
| Previous Close | 122.61 |
| Open | 121.61 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 1800 |
| Day's Range | 120.25 - 121.81 |
| 52 Week Range | 118.62 - 148.32 |
| Volume | 6,787,408 |
| Avg. Volume | 6,624,117 |
| Market Cap | 325.398B |
| Beta | 0.56 |
| PE Ratio (TTM) | 268.41 |
| EPS (TTM) | 0.45 |
| Earnings Date | Jul 17, 2018 |
| Forward Dividend & Yield | 3.60 (2.94%) |
| Ex-Dividend Date | 2018-05-25 |
| 1y Target Est | 145.10 |
Associated Press•9 hours agoMarkets Right Now: Stocks look to recover from early skid
NEW YORK (AP) — The latest on developments in financial markets (all times local):
- TheStreet.com•9 hours ago
3 Great Stocks for Retirees to Own
Congratulations! You've just retired. Investors and financial planners both suggest that dividend stocks can be a great source of income for those looking to supplement their retirement savings. The blue-chip stock's staying power and brand recognition should be viewed favorably by retiree investors, says Robert Johnson, principal at the Fed Policy Investment Research Group.
- Reuters•15 hours ago
After split from Actelion, Idorsia CEO plans to raise more cash in 2019
Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters. French founders Jean-Paul Clozel and his wife, Martine Clozel, sold Actelion for $30 billion last year, but only after extracting rights to 11 prized drugs in development, including an insomnia medicine nicknamed DORA. With 650 employees, Jean-Paul Clozel expects to burn through Idorsia's cash in about two years, before his drug hopefuls generate revenue - typical of the biotech industry where the risk of pipeline failures is ever-present but the rewards of striking paydirt, as was the case with Actelion, can be vast.
- Reuters•16 hours ago
FOCUS-After split from Actelion, Idorsia CEO plans to raise more cash in 2019
Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters. French founders Jean-Paul Clozel and his wife, Martine Clozel, sold Actelion for $30 billion last year, but only after extracting rights to 11 prized drugs in development, including an insomnia medicine nicknamed DORA. With 650 employees, Jean-Paul Clozel expects to burn through Idorsia's cash in about two years, before his drug hopefuls generate revenue - typical of the biotech industry where the risk of pipeline failures is ever-present but the rewards of striking paydirt, as was the case with Actelion, can be vast.
- Motley Fool•17 hours ago
Why Geron Corporation Stock Is Heading Higher Today
The company's EHA conference over the weekend has investors snapping up shares today.
- PR Newswire•17 hours ago
FDA Approves the Next Generation of Customized LASIK Treatment with iDESIGN Refractive Studio
Next generation LASIK platform that measures the eye inside and out to enable highly precise personalized vision correction Only available LASIK platform indicated for monovision LASIK in presbyopic myopic ...
- American City Business Journals•18 hours ago
UNF, Mayo experiment with rare 3-D microscope
The University of North Florida is temporarily housing a highly advanced microscope, the only one of its kind in North America.
- Motley Fool•2 days ago
Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming
Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?
- Motley Fool•2 days ago
Better Buy: Johnson & Johnson vs. Eli Lilly
Which of these big pharma stocks has a better chance to outperform for your portfolio.
- Motley Fool•2 days ago
Better Buy: Pfizer Inc. vs. Johnson & Johnson
How do these two big pharma stocks compare in a head-to-head match?
- Financial Times•2 days ago
[$$] Global pharma bleeds talent to China start-ups
Multinational drug companies in China are fighting to hold on to top talent as senior local staff leave to join a booming domestic biotechnology sector drawing record investment. $11.7bn of venture capital investment in 2017, more than double the $5.3bn invested in 2016, according to consultancy ChinaBio, with about $2.6bn going to drug developers. “I see clearly the opportunity for Chinese companies and for indigenous innovation for patients in China,” said Xiaobin Wu, who was Pfizer’s China manager from 2009 until he joined local cancer drug developer BeiGene last month.
- Moody's•3 days ago
LifeScan Global Corporation -- Moody's downgrades LifeScan Global's term loan B rating to B2 from B1
Moody's Investors Service ("Moody's) downgraded LifeScan Global Corporation's ("LifeScan") first lien term loan rating to B2 from B1. At the same time Moody's affirmed all other ratings of LifeScan as detailed below including the B2 Corporate Family Rating.
- Barrons.com•3 days ago
[$$] Can Investment Performance Be Predicted?
Morningstar’s annual investment conference in Chicago last week was noticeably different than in years past. The 30th iteration focused less on stocks, funds, and other investments, and instead emphasized technology and tools to analyze them. The three-day gathering also served up big-picture thinking from luminaries such as veteran investor and environmental evangelist Jeremy Grantham, and Nobel Prize–winning behavioral psychologist Danny Kahneman.
- InvestorPlace•4 days ago
7 Perfect Dividend Stocks
Dividend reinvestment is an amazingly powerful investment strategy. In fact, studies have shown that over a 20-year holding period, dividends account for 60% of all the gains in the S&P 500! Think about this for a minute. Since 1998, the S&P 500 would be around 60% lower if not for the benefits attributed to dividends.
- Zacks•4 days ago
Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III
Glaxo's (GSK) two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine showed non-inferiority to a standard three-drug regimen
- InvestorPlace•4 days ago
10 Best Stocks to Buy and Hold Forever
In a market environment that overwhelmingly encourages constant activity by investors who seemingly want to double their money every week, a discussion of stocks to buy and hold forever seems comically out of place. Conversely, the fact that Warren Buffett’s favorite holding period is “forever” and how he’s got a track record most investors would envy is just as telling. With that as the backdrop, here’s a rundown of 10 stocks to buy and hold forever … or at least until something significant changes with your life plans or the companies themselves.
- Zacks•4 days ago
Dow 30 Stock Roundup: Caterpillar Raises Dividend, Merck's Keytruda Gets FDA Nod
The Dow traversed a tough week, suffering losses for three consecutive sessions.
- Zacks•4 days ago
Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health
Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health
Markit•4 days agoSee what the IHS Markit Score report has to say about Johnson & Johnson.
Johnson & Johnson NYSE:JNJ
- Simply Wall St.•4 days ago
Estimating The Fair Value Of Johnson & Johnson (NYSE:JNJ)
In this article I am going to calculate the intrinsic value of Johnson & Johnson (NYSE:JNJ) using the discounted cash flows (DCF) model. Anyone interested in learning a bit moreRead More...
- PR Newswire•4 days ago
Kyros Law is Investigating Claims on Behalf of Invokana users: 1,100 Invokana Lawsuits Alleging Diabetic Ketoacidosis, Kidney Injury, Amputations and Heart Complications Filed.
BOSTON , June 14, 2018 /PRNewswire/ -- Kyros Law Offices is alerting individuals that have suffered serious side effects from taking Invokana that it is investigating filing legal claims seeking compensation ...
- Zacks•4 days ago
Growth & Income Buys | Johnson & Johnson and International Paper
This week's video covers two companies where management has made key decisions for the future of their respective companies; Johnson & Johnson (JNJ), and International Paper (IP).
- InvestorPlace•4 days ago
5 AI Biotech Stocks to Bet On Now
Biotech stocks are also capitalizing on AI’s potential to deliver revolutionary drugs and speed up drug discovery. “I believe that AI is a sleeping giant for healthcare in general,” Eric Horvitz, director of Microsoft Research Labs, said earlier this year.
- CNBC Videos•7 hours ago
Cramer floats idea for 'gloomy' ETF with Wall Street's mo...
Jim Cramer proposes starting a new exchange-traded fund with the stocks that scare investors most when trade tensions run high.
- CNBC Videos•7 hours ago
Cramer floats idea for 'gloomy' ETF
Jim Cramer proposes starting a new exchange-traded fund with the stocks that scare investors most when trade tensions run high.
